The ABHD6 Knockout LoVo Polyclonal Cells represent a CRISPR/Cas9-edited population of human colorectal adenocarcinoma cells in which the ABHD6 gene has been disrupted. This polyclonal knockout product comprises a heterogeneous pool of LoVo cells carrying targeted ABHD6 gene modifications, providing a loss-of-function model for studying the serine hydrolase ABHD6. ABHD6 normally hydrolyzes the endocannabinoid 2-arachidonoylglycerol (2-AG), terminating signaling through cannabinoid receptors CB1 and CB2; its disruption allows investigation of endocannabinoid tone and lipid-mediated processes in a colorectal cancer context. As a polyclonal population, the cells retain parental genetic diversity while harboring ABHD6 mutations, making them suitable for pooled functional assays and inhibitor screening.
The host cell line, LoVo, is a human colorectal adenocarcinoma line originally established from a supraclavicular lymph node metastasis. LoVo cells are widely used as an in vitro model for colorectal cancer, particularly for studies of metastasis, drug response, and oncogenic signaling. Their epithelial morphology and characterized mutational landscape provide a physiologically relevant background for examining gene function in colon carcinogenesis. This ABHD6 knockout derivative enables direct isogenic comparison with wild-type LoVo cells, facilitating dissection of ABHD6-dependent phenotypes in a tumor-relevant context.
ABHD6 is a member of the serine hydrolase family that selectively catabolizes 2-AG at intracellular membranes, thereby modulating cannabinoid receptor-driven signaling. Its expression is transcriptionally regulated by peroxisome proliferator-activated receptors PPAR?? and PPAR?? and can be induced by cellular stress. The enzyme coordinates with monoacylglycerol lipase (MAGL) to control 2-AG levels and associates with lipid droplet proteins, positioning it at metabolic interfaces. By reducing 2-AG availability, ABHD6 diminishes CB1/CB2 activation, leading to attenuated MAPK/ERK signaling, release of AMPK inhibition, and production of arachidonic acid for eicosanoid synthesis. This positions ABHD6 as a nexus between endocannabinoid hydrolysis, energy sensing, and inflammation.
In colorectal adenocarcinoma, alterations in endocannabinoid signaling have been implicated in tumor growth and progression. The ABHD6 knockout LoVo model allows direct interrogation of how ABHD6-mediated 2-AG hydrolysis influences colon cancer cell biology. Elevated 2-AG levels resulting from ABHD6 disruption may enhance cannabinoid receptor activity, potentially affecting processes such as proliferation, apoptosis, motility, and drug sensitivity. As a polyclonal knockout population, these cells avoid the artifacts of clonal selection and better reflect heterogeneous tumor responses, enabling robust correlation of ABHD6 function with cancer cell phenotypes.
These polyclonal ABHD6 knockout cells are suited for diverse experimental applications. Knockout confirmation can be performed via western blotting for ABHD6 and RT-qPCR for ABHD6 mRNA, while functional loss is assessed by LC-MS quantification of 2-AG accumulation. Phenotypic profiling includes cell proliferation (MTT, BrdU), migration and invasion assays, apoptosis analysis, and phospho-ERK signaling measurement. Global transcriptional changes can be explored through RNA-seq, and comprehensive lipidomics can map alterations in the endocannabinoid system. The polyclonal format is also ideal for screening ABHD6 inhibitors in dose-response studies. For additional product details and technical support, contact Ascent Research.
